RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
RBC Capital analyst Gregory Renza maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $44.According to TipRanks data, the analyst has a success rate of 46.4
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $45
Wedbush analyst Laura Chico maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and adjusts the target price from $42 to $45.According to TipRanks data, the analyst has a success rate of 47.
Viridian Therapeutics Analyst Ratings
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $44
RBC Capital analyst Gregory Renza maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and adjusts the target price from $35 to $44.According to TipRanks data, the analyst has a success
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Following Positive THRIVE Study Results and Strong Market Potential for Veli